SEC Form PRE 14A filed by Larimar Therapeutics Inc.
$LRMR
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $9.00 | Overweight | Analyst |
| 1/29/2025 | $18.00 | Buy | Truist |
| 10/16/2024 | $26.00 | Outperform | Oppenheimer |
| 10/3/2024 | $22.00 | Outperform | Wedbush |
| 10/2/2024 | $15.00 | Buy | H.C. Wainwright |
| 9/4/2024 | $16.00 | Outperform | Robert W. Baird |
| 4/3/2024 | $25.00 | Outperform | Leerink Partners |
| 11/17/2023 | $4.50 | Neutral → Buy | Citigroup |
Analyst initiated coverage of Larimar Therapeutics with a rating of Overweight and set a new price target of $9.00
Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
10-Q - Larimar Therapeutics, Inc. (0001374690) (Filer)
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journalTopline open label study data to support BLA submission expected in Q2 2026$200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027 BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled "Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling" in the journal Clinical and Translational Science, an official peer-reviewed publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). The article is now available online (link). Nonclinical data across mice, rats, and non-human primates consistently showed that treatm
Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinical outcomes (mFARS, FARS-ADL, 9-HPT, MFIS) observed after 1 year of nomlabofusp treatment could suggest potential for clinical benefit relative to a worsening in a FACOMS natural history st
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company's nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich's ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, September 29, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (do
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and childrenOLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg doseAdolescent PK run-in data e
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.
Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari
BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in